Concentration- and rate-dependent electrophysiological effects of restacorin on isolated canine Purkinje fibres

Naunyn-Schmiedeberg's Archives of Pharmacology
A VarróD A Lathrop

Abstract

The cellular electrophysiological effects of restacorin, a new antiarrhythmic agent were studied using conventional microelectrode techniques in isolated dog cardiac Purkinje fibres. Restacorin (1-30 mumol/l) decreased the maximum rate of rise of the action potential upstroke and action potential amplitude while action potential duration measured at 90% of repolarization was shortened in a concentration-dependent manner during pacing at a constant basic cycle length of 500 ms. The effect of 10 mumol/l restacorin on maximal rate of rise of the action potential upstroke and on action potential duration measured at 90% of repolarization were also studied while varying the constant pacing cycle length between 300 and 5000 ms. The results of these studies indicated a rate-dependent effect of restacorin on the action potential characteristics examined. After abrupt changes in cycle length, 10 mumol/l restacorin slowed the fast component of the relation for restitution of action potential duration from 155.3 +/- 5.2 ms (control, n = 6) to 217.1 +/- 17.8 ms (n = 6, P less than 0.05). In the presence of restacorin (10 mumol/l), a second slow component for recovery of maximal action potential upstroke rising velocity was expressed having...Continue Reading

References

Sep 1, 1978·The American Journal of Physiology·K M BaldwinR E Lewis
Mar 16, 1979·Pflügers Archiv : European journal of physiology·D AttwellC Ojeda
Nov 15, 1978·European Journal of Pharmacology·J K GibsonA L Bassett
May 30, 1989·European Journal of Pharmacology·D A LathropA Schwartz
Feb 1, 1985·Journal of the American College of Cardiology·N IkedaO Hauswirth
Jan 1, 1971·Naunyn-Schmiedebergs Archiv Für Pharmakologie·P Heistracher
Jan 1, 1971·Naunyn-Schmiedebergs Archiv Für Pharmakologie·H TritthartA Fleckenstein
Jan 1, 1970·The Journal of Clinical Investigation·J T Bigger, W J Mandel
Jan 1, 1984·Annual Review of Pharmacology and Toxicology·L M Hondeghem, B G Katzung
Nov 1, 1980·Journal of Molecular and Cellular Cardiology·K R Courtney
Jul 1, 1981·Circulation Research·B F Hoffman, M R Rosen

❮ Previous
Next ❯

Citations

Sep 1, 1997·Medicinal Research Reviews·P MátyusL Virág

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.